P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma by Yap, T., Desai, J., Dagogo-Jack, I., Millward, M., Kindler, H.L., Tolcher, A.W., Frentzas, S., Body, A.L., Thurston, A., Post, L., Dorr, F.A., Kwiatkowski, D.J.

Get full text